Comparing BioLargo (BLGO) & The Competition

BioLargo (NASDAQ:BLGOGet Free Report) is one of 33 publicly-traded companies in the “Chemicals & allied products” industry, but how does it contrast to its peers? We will compare BioLargo to related businesses based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares BioLargo and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLargo -16.53% -58.35% -32.12%
BioLargo Competitors -591.84% 5.15% -0.65%

Volatility and Risk

BioLargo has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.81, meaning that their average share price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for BioLargo and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo 0 0 0 0 N/A
BioLargo Competitors 139 1249 1568 44 2.51

As a group, “Chemicals & allied products” companies have a potential upside of 15.62%. Given BioLargo’s peers higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.

Institutional & Insider Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares BioLargo and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioLargo $12.23 million -$3.50 million -8.17
BioLargo Competitors $6.85 billion $211.64 million 65.96

BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

BioLargo peers beat BioLargo on 8 of the 10 factors compared.

About BioLargo

(Get Free Report)

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.